Skip to main content Skip to main navigation menu Skip to site footer
Bleeding, Thrombosis and Vascular Biology

Editor-in-Chief: Giovanni de Gaetano, Italy | eISSN: 2785-5309

  • About the Journal
  • Publication Ethics
  • Editorial Board
  • Current Issue
  • Archives
  • Copyright
  • Supplements
    • SISET 2025
  • Register
  • Login
  • Search
  • Contacts
0.6
CiteScore 2025
0.6
CiteScore 2025
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • PO55 | Evaluation of safety and efficacy of emicizumab prophylaxis in pediatric patients with hemophilia A – a single centre experience M.L. Tramontano, M. Coppola, S. Coppola, M. Schiavulli | UOSD Centro Regionale Pediatrico Malattie della Coagulazione, Santobono Pausilipon Children Hospital, AORN, Napoli, Italy

    22-10-2025
    https://doi.org/10.4081/btvb.2025.324
    270
    PDF: 0
  • PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience A.L. Faccini, M. Biglietto, S. Sorella, E. Crisanti, M. Antonacci, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro, S. Ligia | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy

    22-10-2025
    https://doi.org/10.4081/btvb.2025.355
    379
    PDF: 0
  • CO34 | Evaluation of emicizumab concentration and thrombin generation in a cohort of severe hemophilia A patients with and without inhibitor A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy

    22-10-2025
    https://doi.org/10.4081/btvb.2025.241
    271
    PDF: 0
  • CO31 | Immune system profiling in FVIII-treated and emicizumab-treated pediatric HA patients A. Cottonaro1, S. Akula1, B. Pollio2, I. Ricca2, T. Martini2, J. Agnelli Giacchello3, P. Sciancalepore3, R. Santi3, A. Follenzi1,3, S. Merlin1 | 1Università del Piemonte Orientale, Health Sciences, Novara; 2A.O. Città della Salute e della Scienza, SIMT Immunohematology and Transfusion Medicine Service, Diagnostic Department, Torino; 3Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

    22-10-2025
    https://doi.org/10.4081/btvb.2025.238
    296
    PDF: 0
  • PO44 | Emicizumab in acquired haemophilia A M. Leotta, A. Strangio, A. Ierardi, S. Prejanò, R C. Santoro | Hemostasis and Thrombosis Unit, Department Hemato-Oncology, Azienda Ospedaliero-Universitaria Renato; Dulbecco, Catanzaro, Italy

    22-10-2025
    https://doi.org/10.4081/btvb.2025.307
    301
    PDF: 0
  • PO24 | Emicizumab prophylaxis and bleeding outcomes: a single center clinical experience A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy

    22-10-2025
    https://doi.org/10.4081/btvb.2025.285
    295
    PDF: 0
  • PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach S. Sorella, J. Micozzi, E. Baldacci, M. Biglietto, R. Mormile, A. Chistolini, R. Ciciani, L. Torrieri, N. Zhdanovskaya, M. Lorenzon, A. Delli Paoli, S. Ligia, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy

    22-10-2025
    https://doi.org/10.4081/btvb.2025.318
    308
    PDF: 0
  • PO67 | Pancreatic cancer in a 71-year-old severe hemophilia A patient with inhibitors and sustained zero bleeding during emicizumab prophylaxis M. Biglietto, A.L. Faccini, S. Sorella, E. Crisanti, M. Antonacci, A. Taglietti, M. Gherardini, A. Tirnetta, S. Ligia, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy

    22-10-2025
    https://doi.org/10.4081/btvb.2025.336
    317
    PDF: 0
  • PO65 | Utilization of emicizumab in acquired hemophilia A: a case report C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, G. D’errico, L. Jr Valletta, M. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

    22-10-2025
    https://doi.org/10.4081/btvb.2025.334
    298
    PDF: 0
  • CO21 | Viscoelastic testing in inherited bleeding disorders: a cross-sectional comparison between viscoelastic coagulation monitoring and rotational thromboelastometry C. Simion, C. Samà, C. Bulato, G. Gottardi, D. Regazzo, E. Campello, P. Simioni | Department of Medicine – DIMED, University of Padua, Italy

    22-10-2025
    https://doi.org/10.4081/btvb.2025.227
    319
    PDF: 0
1 - 10 of 10 items

authors

FOR AUTHORS
  • SUBMIT YOUR PAPER
  • Guide for Authors
  • Benefits for Authors
  • How to write a scientific paper
  • How to write a Review article
  • Index of Authors

reviewers

FOR REVIEWERS
  • Benefits for Reviewers
  • How to review

Categories

    • SISET 2025 - Oral Communications
    • Selected Communications
    • VTE and Cardiovascular Diseases
    • Laboratory and Predictive Factors
    • Congenital and Acquired Hemorrhagic Diseases
    • Platelet Alterations and Genetic Conditions
    • SISET 2025 - Posters
Bleeding, Thrombosis and Vascular Biology

is an Open Access, peer-reviewed journal published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.

eISSN: 2785-5309

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission
  • Guidelines For Authors

Our App Is Free For Anyone!

© PAGEPress 2008-2025    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185    •    Privacy